[
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer",
    "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during",
    "url": "https://finnhub.io/api/news?id=5e28a92f2e8a22f4111f90e97e9c5ce04ff869c0f1192dcaf22e18fffc6311b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760798100,
      "headline": "KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer",
      "id": 137164365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during",
      "url": "https://finnhub.io/api/news?id=5e28a92f2e8a22f4111f90e97e9c5ce04ff869c0f1192dcaf22e18fffc6311b4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
    "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
    "url": "https://finnhub.io/api/news?id=0a43e85f38c582873a9fac40836dfb192f0309f646799345caec66c069f0926b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760797840,
      "headline": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
      "id": 137162458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
      "url": "https://finnhub.io/api/news?id=0a43e85f38c582873a9fac40836dfb192f0309f646799345caec66c069f0926b"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
    "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible f",
    "url": "https://finnhub.io/api/news?id=0017d9660b12eb9471e62bc58c100d5030161b97890c186d5dd3c7bec516d063",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760797800,
      "headline": "KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery",
      "id": 137164367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible f",
      "url": "https://finnhub.io/api/news?id=0017d9660b12eb9471e62bc58c100d5030161b97890c186d5dd3c7bec516d063"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen",
    "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma",
    "url": "https://finnhub.io/api/news?id=b75bfd0b900959ad68c118cd0fac8485edeb1ba5189569f1aee82abb8c7a08a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760781600,
      "headline": "KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen",
      "id": 137164368,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma",
      "url": "https://finnhub.io/api/news?id=b75bfd0b900959ad68c118cd0fac8485edeb1ba5189569f1aee82abb8c7a08a4"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Vs BioNTech: Who's Winning The Post-COVID Race",
    "summary": "Moderna Vs BioNTech: Who's Winning The Post-COVID Race",
    "url": "https://finnhub.io/api/news?id=be3fc31fd328aaa5a2e9c7f6090935d75157a73fe954edd47ad9d5c63049b78c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760779800,
      "headline": "Moderna Vs BioNTech: Who's Winning The Post-COVID Race",
      "id": 137134114,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=be3fc31fd328aaa5a2e9c7f6090935d75157a73fe954edd47ad9d5c63049b78c"
    }
  }
]